Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts

European Journal of Cancer

Volumn 36, Issue 14, 2000, Pages 1869-1875

  Shimada, M ^a   Kigawa, J ^a   Kanamori, Y ^a   Itamochi, H ^a   Takahashi, M ^a   Kamazawa, S ^a   Sato, S ^a   Terakawa, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

CDDP; Ovarian cancer; Recombinant adenovirus; TP53 gene transfer; Xenograft

Indexed keywords

CISPLATIN; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; VIRUS RECOMBINANT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; FEMALE; GENES, P53; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TRANSFORMATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033870825     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00161-1     Document Type: Article

References (30)

1. Boente M., Hurteau J., Rodriguez G.C., Bast R.C. Jr., Berchuck A. The biology of ovarian cancer. Curr. Opin. Oncol. 5:1993;900-907.
2. Perez R.P., Hamilton T.C., Ozols R.F., Young R.C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 71:1993;1571-1580.
3. Kigawa J., Minagawa Y., Ishihara H., Kanamori Y., Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer. 2:1993;804-808.
4. Muggia F.M. Cisplatin update. Semin. Oncol. 18:1991;1-4.
5. Thigpen J.T., Bertelsen K., Eisenhauer E.A., Hacker N.F., Lund B., Sessa C. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann. Oncol. 4:1993;35-40.
6. Anderson S.C., Johnson D.E., Harris M.P.et al. p53 gene therapy in a rat model of hepatocellular carcinoma. intra-arterial delivery of a recombinant adenovirus Clin. Cancer Res. 4:1998;1649-1659.
7. Nielsen L.L., Dell J., Maxwell E., Armstrong L., Maneval D., Catino J.J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4:1997;129-138.
8. Qazilbash M.H., Xiao X., Seth P., Cowan K.H., Walsh C.E. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 4:1997;675-682.
9. Kock H., Harris M.P., Anderson S.C.et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer. 67:1996;808-815.
10. Kanamori Y., Kigawa J., Minagawa Y.et al. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur. J. Cancer. 34:1998;1802-1806.
11. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
12. Kastan M.B., Canman C.E., Leonard C.J. p53 cell cycle control and apoptosis. implications for cancer Cancer Metast. Rev. 14:1995;3-15.
13. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
14. Okada M., Kigawa J., Minagawa Y.et al. Alterations of the p53 gene and p53 protein expression in epithelial ovarian cancer before and after chemotherapy. Int. J. Clin. Oncol. 3:1998;240-246.
15. Miyake S., Makimura M., Kanegae Y.et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA. 93:1996;1320-1324.
16. Kubota T., Nakada M., Tsuyuki K.et al. Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn. J. Cancer Res. 77:1986;502-507.
17. Gjerset R.A., Turla S.T., Sobol R.E.et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinogen. 14:995;275-285.
18. Lu S.J., Man S., Bani M.R.et al. Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum (II) resistance. Cancer Res. 55:1995;1139-1145.
19. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4:1998;835-846.
20. Nguyen D.M., Spitz F.R., Yen N., Cristiano R.J., Roth J.A. Gene therapy for lung cancer. enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer Thorac. Cardiovasc. Surg. 112:1996;1372-1377.
21. Lowe S.W., Bodis S., McClatchey A.et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
22. Landesman Y., Bringold F., Kimchi A. p53 undergoes eitopic changes in vitro by sodium-vanadate. Oncogene. 9:1994;1241-1245.
23. Righetti S.C., Della T.G., Pilotti S.et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:1996;689-693.
24. Williams G.T., Smith C.A. Molecular regulation of apoptosis. genetic controls on cell death Cell. 74:1993;777-779.
25. Maestro R., Dolcetti R., Gasparotto D.et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene. 7:1992;1159-1166.
26. Deb S., Jackson C.T., Subler M.A., Martin D.W. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:1992;6164-6170.
27. Gorgoulis V., Zoumpourlis V., Rassidakis G.et al. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labeling index. Virchows. Arch. 426:1995;339-344.
28. Jonathan J., Herod J.J., Eliopoulos A.G.et al. The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res. 56:1996;2178-2184.
29. Perego P., Giarola M., Righetti S.et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:1996;556-562.
30. Zhan Q., Carrier F., Fornace A.J. Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol. 13:1993;4242-4250.